• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Liberal RBC Transfusions Do Not Increase Mortality

December 19, 2014

85758144It has been hypothesized that blood transfusions may lead to increased risk of subsequent infections, cancer, and possibly death. The FOCUS trial was a multi-center, randomized, controlled trial that enrolled more than 2,000 patients over 50 years-old who underwent surgery to repair a hip fracture and who were at risk or had a history of cardiovascular disease.

Patients were randomly assigned to either receive liberal RBC transfusions (to maintain hemoglobin >100 g/L) or restrictive RBC transfusions (hemoglobin >80 g/L or anemia symptoms); baseline characteristics were similar in both groups. The original trial previously showed a restrictive RBC transfusion strategy is as safe as a liberal transfusion strategy. In a secondary analysis, recently published in The Lancet, the long-term effects of liberal verses restrictive transfusions were evaluated. Patients had a median follow-up period of 3.1 years. Mortality did not significantly differ between patients receiving liberal transfusions verses those in the restrictive transfusion group. Moreover, the causes of death from cardiovascular disease, cancer and infections were nearly identical in both groups.

References

1. Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, Fleisher L, Beaupre L, Macaulay W, Rads GG, Paris B, Zagorin A, Sanders DW, Zakriya KJ, Magaziner J. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. The Lancet 2014; in press.
2. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J, Investigators F. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365: 2453-62.

Filed Under

  • Adverse Events (non-infectious)
  • News
  • RBC Transfusion

Recommended

  • AABB Bulletin Highlights Recommendations to Reduce the Risk of Transfusion-Related Acute Lung Injury (TRALI)

  • VIDEO: Randomized Trial Demonstrates No Benefit of Fresh Red Cells for Transfusion

  • Long-term Survival of Severe Trauma Patients Treated with Tranexamic Acid

Show Comments

Reader Interactions

Comments

  1. Dr García Erce says

    October 16, 2015 at 3:51 pm

    “Mortality did not significantly differ between patients receiving liberal transfusions verses those in the restrictive transfusion group”

    But, patients receiving “liberal transfusions” did not live more, did not walk more, have not less infection, have not better outcomes, have not better perform, did not walk longer neither stronger.

    So, do not misuse some valuable resource if do not have clear benefit, and if you have safer and cheaper alternatives (like iv iron)

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley